Книги: "Cardioprotective"

1

Kendall, Martin J. Preventing coronary artery disease: Cardioprotective therapeutics in practice. 2nd ed. London: Martin Dunitz, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

M, Beale C., ed. The cardioprotective role of HRT: A clinical update. New York: Parthenon Pub. Group, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

(Germany)), Freiburg Focus on Biomeasurement (9th 1995 Freiburg im Breisgau. Pharmacological evaluation of cardioprotective substances: Experimental induction and indicators of myocardial injury and myocardial protection. Buchenbach, Germany: Gesellschaft für Erfahrungstransfer in der Biomesstechnik e.V., 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Cardioprotection. Oxford: Oxford University Press, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

International Symposium, Calcium Antagonists in Cardiovascular Care (1991 : Basle, Switzerland), ed. Verapamil-- a cardioprotective strategy: Highlights from a satellite symposium to the International Symposium, Calcium Antagonists in Cardiovascular Care, Basle, Switzerland, Feb. 13, 1991. New York, NY: Raven Health Care Communications, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Minatoguchi, Shinya. Cardioprotection Against Acute Myocardial Infarction. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-15-0167-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Baxter, G. F., and D. M. Yellon, eds. Delayed Preconditioning and Adaptive Cardioprotection. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-011-5312-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

F, Baxter G., and Yellon Derek M, eds. Delayed preconditioning and adaptive cardioprotection. Dordrecht: Kluwer Academic Publishers, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Mentzer, Robert M., Masafumi Kitakaze, James M. Downey, and Masatsugu Hori, eds. Adenosine, Cardioprotection and Its Clinical Application. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4419-8736-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

M, Mentzer Robert, ed. Adenosine, cardioprotection, and its clinical application. Boston: Kluwer Academic Publishers, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Przyklenk, Karin, Robert A. Kloner, and Derek M. Yellon, eds. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2602-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

1956-, Przyklenk Karin, Kloner Robert A, and Yellon Derek M, eds. Ischemic preconditioning: The concept of endogenous cardioprotection. Boston: Kluwer Academic Publishers, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Sutter, Johan De, Miguel Mendes, and Oscar H. Franco. Cardioprotective drugs. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656653.003.0019.

Повний текст джерела

Анотація:

Cardioprotective drugs are important in the treatment of patients at risk for or with documented cardiovascular disease. Beta-blockers are indicated after acute coronary syndromes, stable coronary artery disease, heart failure, and arrhythmias. Angiotensin-converting enzyme inhibitors (ACEi) are important in congestive heart failure, stable angina, post-acute myocardial infarction, and secondary prevention after any event or revascularization. Angiotensin receptor blockers are mainly alternative drugs for the same indications in case of intolerance to ACEi. Calcium channel blockers are first line medication for patients with isolated systolic hypertension, black people, and during pregnancy, in the presence of intermittent claudication, asymptomatic atherosclerosis, or metabolic syndrome. A polypill is a combination pill in which multiple medications effective in the prevention of cardiovascular disease (for example statins, antihypertensives, and aspirin) are put together in a single pill.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Sutter, Johan De, Miguel Mendes, and Oscar H. Franco. Cardioprotective drugs. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199656653.003.0019_update_001.

Повний текст джерела

Анотація:

Cardioprotective drugs are important in the treatment of patients at risk for or with documented cardiovascular disease. Beta-blockers are indicated after acute coronary syndromes, stable coronary artery disease, heart failure, and arrhythmias. Angiotensin-converting enzyme inhibitors (ACEi) are important in congestive heart failure, stable angina, post-acute myocardial infarction, and secondary prevention after any event or revascularization. Angiotensin receptor blockers are mainly alternative drugs for the same indications in case of intolerance to ACEi. Calcium channel blockers are first line medication for patients with isolated systolic hypertension, black people, and during pregnancy, in the presence of intermittent claudication, asymptomatic atherosclerosis, or metabolic syndrome. A polypill is a combination pill in which multiple medications effective in the prevention of cardiovascular disease (for example statins, antihypertensives, and aspirin) are put together in a single pill.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Brahmachari, Goutam. Cardioprotective Natural Products. WORLD SCIENTIFIC, 2017. http://dx.doi.org/10.1142/10740.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Hausenloy, Derek, and Derek Yellon, eds. Novel Cardioprotective Strategies. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0011.

Повний текст джерела

Анотація:

• Despite optimal therapy, the mortality and morbidity of coronary heart disease remains significant. Hence, novel treatment strategies of cardioprotection are required to improve clinical outcomes in these patients• Experimental studies have provided a plethora of therapeutic strategies for reducing myocardial injury, but the translation of these findings into the clinical setting has been largely disappointing. Many of these unsuccessful clinical studies have relied upon individually targeting established mediators of lethal reperfusion injury such as oxidative stress, inflammation, calcium overload and so forth• Clearly, novel targets for cardioprotection as well as a multi-targeted approach to cardioprotection directed against the multiple causes of lethal reperfusion injury are required to effect benefits in clinical outcomes• In this regard, the introduction of ischaemic postconditioning, a novel treatment strategy, in which following primary PCI the process of myocardial reperfusion is interrupted by several coronary re-occlusions, has been reported to reduce myocardial myocardial injury in AMI patients• Furthermore, experimental studies have identified the Reperfusion Injury Salvage Kinase (RISK) pathway and the mitochondrial permeability transition pore (mPTP) as novel targets for cardioprotection, which are currently been examined in the clinical setting.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Hausenloy, Derek, and Derek Yellon, eds. An Introduction to Cardioprotection. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0001.

Повний текст джерела

Анотація:

• In its broadest sense, the term ‘cardioprotection’ encompasses ‘all mechanisms and means that contribute to the preservation of the heart by reducing or even preventing myocardial damage’• However, for the purposes of this book, the term ‘cardioprotection’ will refer to the endogenous mechanisms and therapeutic strategies that reduce or prevent myocardial damage induced by acute ischaemia-reperfusion injury• In this context, cardioprotection begins with the primary prevention of coronary heart disease and includes the reduction of myocardial injury sustained during coronary artery bypass graft surgery, and an acute myocardial infarction, conditions with considerable morbidity and mortality• An understanding of the pathophysiology of acute myocardial ischaemia-reperfusion injury is essential when designing new cardioprotective strategies• Several methods exist for both quantifying myocardial damage induced by acute ischaemia-reperfusion injury and for assessing myocardial salvage following the application of cardioprotective strategies• Importantly, novel cardioprotective strategies must be capable of preventing and reducing myocardial damage over and above that provided by current optimal therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Brahmachari, Goutam. Cardioprotective Natural Products: Promises and Hopes. World Scientific Publishing Co Pte Ltd, 2017.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Horton, Richard C., and Martin J. Kendall. Preventing Coronary Artery Disease: Cardioprotective Therapeutics in the 1990s. Scovill-Paterson, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Publishers, Collins. Cardioprotective Role of Hrt a Clinical Update Portugeuse E. Taylor & Francis Group, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Pepper, John. Cardioprotection During Cardiac Surgery. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0007.

Повний текст джерела

Анотація:

• Overall early mortality for cardiac surgery is low at 2–3% but in high risk patients it can be high as 10–15%• The demography of cardiac surgical patients is changing to older and sicker patients• Myocardial ischaemia-reperfusion injury and the systemic inflammatory response are closely related• Several pharmacological agents that have been demon-strated to confer cardioprotection in the experimental setting have been applied to the clinical setting of cardiac surgery. However, the transfer of these findings from the bench to the bedside has been largely disappointing• Potential cardioprotective strategies include pharma-cological agents such as adenosine, and mechanical interventional strategies such as acute normovolaemic haemodilution and remote ischaemic preconditioning.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Downey, James, and Michael Cohen. Endogenous Mechanisms of Cardioprotection. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0008.

Повний текст джерела

Анотація:

• Ischaemic preconditioning is the most powerful endogenous mechanism for limiting myocardial infarct size in the experimental setting. Its clinical application is limited to scenarios in which the index episode of ischaemia and reperfusion can be anticipated such as in the setting of cardiac surgery• Ischaemic postconditioning represents an endogenous cardioprotective strategy which is applied at the onset of myocardial reperfusion, thereby allowing its use as an adjunct to reperfusion in patients presenting with an acute myocardial infarction• Both ischaemic preconditioning and postconditioning recruit a common signal transduction pathway at the time of myocardial reperfusion, which can be targeted by pharmacological agents administered as adjuncts to reperfusion.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Momin, Firoz, Nilofar Naikwade, and Tabassum Shikalgar. Cardioprotective Effect of Combination of Enalapril and Fenofibrate: A Hemodynamic, Biochemical and Histopathological Study. LAP Lambert Academic Publishing, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Dallongeville, Jean, Deborah Lycett, and Monique Verschuren. Nutrition. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656653.003.0011.

Повний текст джерела

Анотація:

Different aspects of the human diet are causally related to atherosclerosis and its clinical consequences; therefore a balanced and healthy diet is the cornerstone of the prevention of cardiovascular disease. In this chapter an overview is given of the medical evidence supporting the importance of nutrition in prevention of cardiovascular disease; practical ways to cultivate cardioprotective dietary habits are summarized not only in terms of macro- and micronutrients but also in relation to foods, functional foods. and portfolio diets.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Hausenloy, Derek, and Derek Yellon, eds. Cardioprotection. Oxford University Press, 2009. http://dx.doi.org/10.1093/med/9780199544769.001.0001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Hausenloy, Derek, and Derek Yellon. Cardioprotection. Oxford University Press, 2014.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Hausenloy, Derek, and Derek Yellon. Cardioprotection. Oxford University Press, Incorporated, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Tiezzi, Antonio, Elisa Ovidi, and Tomasz M. Karpiński, eds. New Findings from Natural Substances. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150514211220101.

Повний текст джерела

Анотація:

New Findings from Natural Substances present the state-of-the-art and future prospects for the application of biomolecules in the pharmaceutical, agricultural, food and industrial sectors. The book presents eight reviews contributed by more than twenty experts on interesting natural substances, and plant sources, that serve as sources of natural remedies for a variety of ailments. The reviews in the book cover the use of herbs like Heliotropium and Astragalus. Additional health benefits of extracts from essential oils, Caenorhabditis elegans, and olive oil, as well as the medicinal use of rosmarinic acid and hydrolates. The contributions highlight a range of pharmacological agents from natural sources that have anti-cancer, anti-inflammatory, cardioprotective and neuroprotective effects. The contents are presented in a simple and organized style. The book will broaden the knowledge about biological products for a variety of readers - generalists, students and researchers, alike.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Kendall, Marion D. Beta Blockade and Cardioprotection. Science Press, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Penna, Claudia, Nina Kaludercic, Valentina Mercurio, and Nazareno Paolocci, eds. Cardioprotection, Sex and Gender Differences. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-83250-207-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Minatoguchi, Shinya. Cardioprotection Against Acute Myocardial Infarction. Springer Singapore Pte. Limited, 2021.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Yellon, Derek M., and G. F. Baxter. Delayed Preconditioning and Adaptive Cardioprotection. Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Minatoguchi, Shinya. Cardioprotection Against Acute Myocardial Infarction. Springer, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Yellon, Derek M., and G. F. Baxter. Delayed Preconditioning and Adaptive Cardioprotection. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Kitakaze, Masafumi, James M. Downey, Masatsugu Hori, and Robert M. Mentzer Jr. Adenosine, Cardioprotection and Its Clinical Application. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Jr, Robert M. Mentzer. "Adenosine, Cardioprotection and Its Clinical Application". Springer, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Yellon, Derek M., Robert A. Kloner, and Karin Przyklenk. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Springer My Copy UK, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Yellon, Derek M., Robert A. Kloner, and Karin Przyklenk. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Cell Survival Programs And Ischemiareperfusion Hormesis Preconditioning And Cardioprotection. Biota Publishing, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Korthuis, Ronald, Maike Krenz, Theodore Kalogeris, and Christopher Baines. Cell Survival Programs and Ischemia/Reperfusion: Hormesis, Preconditioning, and Cardioprotection. Morgan & Claypool Life Science Publishers, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Pathophysiology of Ischemia Reperfusion Injury and Use of Fingolimod in Cardioprotection. Elsevier, 2019. http://dx.doi.org/10.1016/c2018-0-02692-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Ahmed, Naseer, and Soban Sadiq. Pathophysiology of Ischemia Reperfusion Injury and Use of Fingolimod in Cardioprotection. Elsevier Science & Technology, 2019.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Ahmed, Naseer. Pathophysiology of Ischemia Reperfusion Injury and Use of Fingolimod in Cardioprotection. Elsevier Science & Technology Books, 2019.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

(Editor), Karin Przyklenk, Robert A. Kloner (Editor), and D. M. Yellon (Editor), eds. Ischemic `Preconditioning': The Concept of Endogenous Cardioprotection (Developments in Cardiovascular Medicine). Springer, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Boloorchi, Azadeh. The role of protein kinase C-epsilon (PKCepsilon) in ischemic preconditioning cardioprotection induced by enhancement of cell volume regulation. 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Cardioprotective"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями